P/B
2,1
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
$572.3M
Market Cap • 9/25/2026
2016
(10 years)
Founded
2023
(3 years ago)
IPO
NASDAQ
Listing Exchange
Switzerland
Country
Valuation
P/S
389,7
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
4,7
EPS
—
Market Cap
Market Cap
572,3M
EV
293,1M
EV/Revenue
199,6
EV/EBITDA
-2,7
EV/EBIT
-2,7
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-30,6%
Total Yield
-30,6%
Payout
0%
Retained Earnings
-523,4M
Profitability
Gross Margin
100%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
4833,7%
Capex/Revenue
15,7%
Capex/D&A
28,7%
Capex/OCF
-0,3%
SBC/OCF
—
% PPE
1,3%
% Goodwill
0%
ROE
—
ROIC
—
Leverage
N.D./EBITDA
2,6
Debt/Equity
0%
Current Ratio
8,3
Quick Ratio
8,2
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!